{
  "abstract": "Background and Importance Drug repositioning is a recent and growing concept involving the research of new indications for a drug at a lower development cost. Thalidomide is an example of a successful drug repositioning. 1 Aim and Objectives The objective was to analyse clinical trial data in order to describe the characteristics of repurposing clinical trials in comparison with other trials.Material and Methods All drug-related clinical trials were extracted from clinicaltrials.gov. For each drug, key pharmacological and administrative data were retrieved from Drugbank. A drug was considered repurposed if the protocol submission date was over 20 years after its patent date. Main trial features (phases, age, number of subjects, funding, study status and ATC class) were compared between repurposed and non-repurposed drugs.Results In total, 96705 trials were extracted from the database of which 21361 were repositioning studies. The distribution of repositioning clinical trials was similar across all trial phases (from 1 to 4).The proportion of clinical trials involving children was similar for repurposing clinical trials compared to other clinical trials. The same was true for clinical trials involving only adults.The average number of participants was 2632 ± 189 in repositioning studies, compared to 871 ± 34 (p<0.001).Only 12% of industry studies corresponded to repositioning, compared with 27% for other funding sources (p<0.001).Less studies involving repositioned drugs were completed (41%) compared to other trials (66%) (p<0.001).We looked at ATC class (level 3). The most represented classes (antineoplastics had the most studies with 22887 trials, followed by antidiabetics, antivirals, etc.) were different from classes most frequently repositioned (anthelmintics 61% of the time, followed by antiinflammatory products, stomatological preparations, etc.).Conclusion and Relevance Our study has limitations, particularly with regard to the method used to define a repositioning study. Nevertheless, certain factors studied were surprisingly similar such as study phase and age of patients.However, the completion levels were much lower with repositioning studies. Industry funding was also much lower. This suggests lower funding in repositioning studies.Differences in ATC class illustrate a gap between traditional research and repurposing of older molecules.References and/or Acknowledgements 1. Jourdan J-P, et al. Drug repositioning: a brief overview. J. Pharm. Pharmacol., 2020;72(9):1145–1151.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospices Civils De Lyon- Croix-Rousse Hospital, Pharmacy Department, Lyon, France"
      ],
      "name": "E Bourguignon"
    },
    {
      "affiliations": [
        "Hospices Civils De Lyon- Croix-Rousse Hospital, Pharmacy Department, Lyon, France"
      ],
      "name": "M Talocci"
    },
    {
      "affiliations": [
        "Hospices Civils De Lyon- Croix-Rousse Hospital, Pharmacy Department, Lyon, France"
      ],
      "name": "M Djeghroud"
    },
    {
      "affiliations": [
        "Hospices Civils De Lyon- Croix-Rousse Hospital, Pharmacy Department, Lyon, France"
      ],
      "name": "L Bourguignon"
    }
  ],
  "title": "6ER-041 Observational study of clinical trials involving drug repositioning",
  "uid": "1b17c786-9acc-57cc-85cf-491f7de80540"
}